Alemtuzumab: egy új terápia előnyei és kihívásai sclerosis multiplexben

Zsolt Illés, Tobias Sejbaek, Tünde Csépány

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

The widening spectrum of MS treatment is partially due to increasing knowledge about the pathogenesis of MS. The humanized monoclonal antibody against CD52, alemtuzumab has been approved in Europe for the treatment of MS, which results in long-term depletion of B and T cells due to complement- and antibody-mediated cytotoxicity. Based on phase 2 and 3 clinical trials, alemtuzumob decreases the risk of sustained neurological deficit and progression compared to high-dose subcutaneous interferon-β1a in patients with active relapsing-remitting MS, either treatment-naïve or with breakthrough disease. We review advantages and benefits of the treatment, discuss safety concerns, and present a case to describe practical issues.

Bidragets oversatte titelALEMTUZUMAB: Benefits and challenges of new therapy in multiple sclerosis
OriginalsprogUngarnsk
TidsskriftIdeggyogyaszati Szemle
Vol/bind68
Udgave nummer5-6
Sider (fra-til)155-164
ISSN0019-1442
DOI
StatusUdgivet - 30. maj 2015

Emneord

  • Adjuvants, Immunologic
  • Adult
  • Antibodies, Monoclonal, Humanized
  • Brain
  • Clinical Trials as Topic
  • Disease Progression
  • Drug Administration Schedule
  • Europe
  • Female
  • Humans
  • Interferon beta-1a
  • Interferon-beta
  • Magnetic Resonance Imaging
  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Myelitis, Transverse
  • Spinal Cord
  • Treatment Outcome
  • Multiple sclerosis
  • Relapse
  • Secunder autoimmunity
  • UP
  • EDSS
  • Alemtuzumab
  • Interferon-j31 a

Fingeraftryk Dyk ned i forskningsemnerne om 'Alemtuzumab: egy új terápia előnyei és kihívásai sclerosis multiplexben'. Sammen danner de et unikt fingeraftryk.

  • Citationsformater